Cytokinetics
CYTK
347 hedge funds and large institutions have $7.2B invested in Cytokinetics in 2024 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 147 increasing their positions, 94 reducing their positions, and 41 closing their positions.
81% more call options, than puts
Call options by funds: $278M | Put options by funds: $154M
56% more repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 94
12% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 41
1% more funds holding
Funds holding: 343 → 347 (+4)
2% less capital invested
Capital invested by funds: $7.34B → $7.2B (-$134M)
2.32% less ownership
Funds ownership: 118.14% → 115.82% (-2.3%)
25% less funds holding in top 10
Funds holding in top 10: 20 → 15 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$86.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$45M |
| 3 |
BlackRock
New York
|
+$32.3M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.8M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$27.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$246M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$32M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
-$30.2M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$27M |
| 5 |
AG
Artal Group
Luxembourg
|
-$26.8M |
CYTK Hedge Fund Activity: Q3 2024 in Review
347 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2024, worth a combined $7.2B — down 1.8% from $7.34B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new CYTK positions and 41 closed out — a net gain of 5 holders — while 147 added to existing stakes and 94 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $86.5M. The largest seller was Darwin Global Management, exiting entirely with an estimated $246M sold.
- 347 institutional investors held Cytokinetics (CYTK) as of Q3 2024, up from 343 in Q2 2024.
- Funds reported $7.2B of Cytokinetics stock for Q3 2024, down 1.8% quarter-over-quarter.
- 46 funds opened new Cytokinetics positions in Q3 2024 and 41 closed out, a net change of +5 holders.
- The largest Cytokinetics buyer in Q3 2024 was T. Rowe Price Investment Management, an estimated $86.5M added.
- The largest Cytokinetics seller in Q3 2024 was Darwin Global Management, an estimated $246M sold.
Based on aggregated 13F filings for Q3 2024.